BridgeBio Days Sales Outstanding from 2010 to 2025

BBIO Stock  USD 32.19  0.82  2.48%   
BridgeBio Pharma Days Sales Outstanding yearly trend continues to be very stable with very little volatility. Days Sales Outstanding is likely to drop to 7.38. During the period from 2010 to 2025, BridgeBio Pharma Days Sales Outstanding quarterly data regression pattern had sample variance of  1,081 and median of  103.40. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
7.76707736
Current Value
7.38
Quarterly Volatility
32.87647713
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 18.1 M, Depreciation And Amortization of 6.4 M or Interest Expense of 104.3 M, as well as many indicators such as Price To Sales Ratio of 21.86, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 7.38. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
  
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Latest BridgeBio Pharma's Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of BridgeBio Pharma over the last few years. It is BridgeBio Pharma's Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Slightly volatile
   Days Sales Outstanding   
       Timeline  

BridgeBio Days Sales Outstanding Regression Statistics

Arithmetic Mean87.81
Geometric Mean71.55
Coefficient Of Variation37.44
Mean Deviation23.39
Median103.40
Standard Deviation32.88
Sample Variance1,081
Range96.0164
R-Value(0.70)
Mean Square Error595.40
R-Squared0.49
Significance0
Slope(4.81)
Total Sum of Squares16,213

BridgeBio Days Sales Outstanding History

2025 7.38
2024 7.77
2023 68.7
2022 80.28

About BridgeBio Pharma Financial Statements

BridgeBio Pharma investors utilize fundamental indicators, such as Days Sales Outstanding, to predict how BridgeBio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Days Sales Outstanding 7.77  7.38 
When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.88)
Revenue Per Share
1.193
Quarterly Revenue Growth
2.371
Return On Assets
(0.48)
Return On Equity
(17.90)
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.